Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors

Drugs of Today

Volumn 32, Issue 1, 1996, Pages 39-55

  Appel, Silke ^a   Dingemanse, Jasper ^a  

^a Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT; COLESTYRAMINE; CYCLOSPORIN A;

AGE; BIOAVAILABILITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; REVIEW; PHARMACOKINETICS;

EID: 0029962009     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1996.32.1.354180     Document Type: Review

References (55)

1. Davignon, J., Montigny, M., Dufour, R. HMG-CoA reductase inhibitors: A look back and a look ahead. Can J Cardiol 1992, 8: 843-64.
2. Kantner, T.R. HMG-CoA reductase inhibitors for treatment of hyperlipidemia. Amer Fam Physician 1993, 47: 1623-7.
3. Mol, M.J.T.M., Stalenhoef, A.F.H. HMG-CoA reductase inhibitors. Curr Opin Lipidol 1993. 4: 41-8.
4. National Cholesterol Education Program (NCEP). Second Report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994, 89: 1333-445.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383-9.
6. Pyörälä, K., De Backer, G., Graham, I., Poole-Wilson, P., Wood, D. on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994, 15: 1300-31.
7. Kathawala, F.G. Exciting developments in the area of HMG-CoA reductase inhibitors. In: Van der Goot, H., Domány, G., Pallos, L., Timmerman, H. (Eds.). Trends in Medicinal Chemistry 88. Elsevier Science Publishers B.V.: Amsterdam 1989, 709-28.
8. Kathawala, F.G. HMG-CoA reductase inhibitors: An exciting development in the treatment of hyperlipoproteinemia. Med Res Rev 1991, 11: 121-46.
9. Karara, A.H., Abolin, C.R. Fluvastatin. A report describing the chiral disposition of XU 62-320 enantiomers in several clinical and preclinical studies. Sandoz Pharma Ltd. 1991. Data on file.
10. Smith, H.T., Jokubaitis, L.A., Troendle, A.J., Hwang, D.S., Robinson, W.T. Pharmacokinetics of fluvastatin and specific drug interactions. Amer J Hypertens 1993, 6: 375-82S.
11. Sandoz Pharma Ltd. 1994. Data on file.
12. Kalafsky, G., Smith, H.T. High-performance liquid chromatographic method for the determination of fluvastatin in human plasma. J Chromatogr 1993, 614: 307-13.
13. Tse, F.L.S., Jaffe, J.M., Troendle, A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 1992, 32: 630-8.
14. Choc, M.G., Hsuan, F., Troendle, A. A study to characterize the dose bioavailability relationship of XU 62-320 (fluvastatin sodium) following single dose administration of 10, 20 and 40 mg as an oral solution. Sandoz Pharma Ltd. 1989. Data on file.
15. Smith, H.T., Hsuan, F., Troendle, A.J. A study to characterize the dose-bioavailability relationship of 10, 20, and 40 mg of fluvastatin (XU 62-320) administered as (1, 2, or 4) 10 mg service capsules. Sandoz Pharma Ltd. 1991. Data on file.
16. Tse, F.L.S, Nickerson, D.F., Yardley, W.S. Binding of fluvastatin to blood cells and plasma proteins. J Pharm Sci 1993, 82: 942-7.
17. Guillot, R. Misslin, P., Lemaire, M. Comparison of fluvastatin and lovastatin blood-brain barrier transfer using in vitro and in vivo methods. J Cardiovasc Pharmacol 1993, 21: 339-46.
18. Tse, F.L.S, Labbadia, D. Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit. Biopharm Drug Dispos 1992, 13: 285-94.
19. 3H into rat milk. Sandoz Pharma Ltd. 1989. Data on file.
20. Dain, J.G., Fu, E., Gorski, J., Nicoletti, J., Scallen, T.J. Biotransformation of fluvastatin sodium in humans. Drug Metab Dispos 1993, 21: 567-72.
21. Fischer, V., Baldeck, P. Fluvastatin (XU 62-320). Effect on CYP2C and on the metabolism of oral antidiabetics. Sandoz Pharma Ltd. 1994. Data on file.
22. Transon, C., Leemann, T., Dayer, P. Selective in vitro P450 inhibition profile by fluvastatin indicates its potential in vivo drug interactions. Clin Pharmacol Ther 1993, 53: 188.
23. Dettinger, H.M., Kölle, E.U., Karara, A.H., Ackermann, W., Lundqvist, T., Pacha, W. Pharmacokinetics of XU62-320 after single and multiple oral dosing and effect of XU62-320 on the mixed function oxidase system assessed by antipyrine clearance in poor and extensive metabolizers for sparteine. Sandoz Pharma Ltd. 1992. Data on file.
24. Parker, T.S., McNamara, D.J., Brown, C. et al. Mevalonic acid in human plasma: Relationship of concentration and rhythm to cholesterol synthesis rates in man. Proc Circadian Natl Acad Sci 1982, 79: 3037-41.
25. Dujovne, C.A., Davidson, M.H. Fluvastatin administration at bedtime versus with the evening meal: A multicenter comparison of bioavailability, safety and efficacy. Amer J Med 1994, 96: (Suppl. 6A): 37-40.
26. McLeod, J., Chang, C-T., Kalafsky, G. et al. A randomized, open label, parallel group study to determine single dose and steady-state fluvastatin pharmacokinetics after administration of Lescof 20 mg and 40 mg twice daily, and to evaluate pharmacokinetic/pharmacodynamic relationships in subjects with hypercholesterolemia. Sandoz Pharma Ltd. 1995. Data on file.
27. Jacotot, B., Benghozi, R., Pfister, P., Holmes, D. on behalf of the French Fluvastatin Study Group. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. Amer J Cardiol 1995, 76: 54A-56A.
28. Bristol-Myers Squibb Co. Pravachol. Pravastatin sodium tablets. Physicians' Desk Reference 1994.
29. Merck and Company. Mevacor tablets and Zocor tablets. Lovastatin and Simvastatin. Physicians' Desk Reference 1994.
30. Gwynne, J.T., Appel, S., Kalafsky, G., Thebault, J.J. A study on the pharmacokinetics of fluvastatin in patients with renal insufficiency following a single oral administration. Sandoz Pharma Ltd. 1996, in preparation.
31. Lintott, C.J., Scott, R.S., Bremer, J.M., Shand, B.I. Fluvastatin for dyslipoproteinemia with or without concomitant chronic renal insufficiency. Amer J Cardiol 1995, 76: 97A-101A.
32. Appel, S., Dingemanse, J. Pharmacokineticand pharmacodynamic interactions of fluvastatin and their therapeutic implications. Rev Contemp Pharmacother 1996, 7: 167-82.
33. Levy, R.I., Troendle, A.J., Fattu, J.M. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993, 82: (Suppl. III): 45-53.
34. Blum, C.B. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutarylcoenzyme A reductase. Amer J Cardiol 1994, 73: 3-11D.
35. Garnett, W.R. The pharmacology of fluvastatin, a new HMG-CoA reductase inhibitor. Clin Cardiol 1994, 17 (Suppl. IV): 3-10.
36. Jokubaitis, L.A. Updated clinical safety experience with fluvastatin. Amer J Cardiol 1994, 73: 18-24D.
37. Kellick, K.A., Ellis, A.K. Focus on fluvastatin. The first totally synthetic HMG-CoA reductase inhibitor for treatment of hypercholesterolemia. Hosp Formul 1994, 29: 245-50.
38. Plosker, G.L., Wagstaff, A.J. Fluvastatin. A review of its pharmacology and use in the management of hypercholesterolemia. Drugs 1995, 50: 854-78.
39. McKenney, J.M. Lovastatin: A new cholesterollowering agent. Clin Pharm 1988, 7: 21-36.
40. Mauro, V.F. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993, 24: 195-202.
41. Quion, J.A.V., Jones, P.H. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 1994, 27: 94-103.
42. Fukuo, Y., Akaishi, H., Honda, H. et al. Differences in rate of hydrolysis of HMG-CoA reductase inhibitors in human and animal tissues. Atherosclerosis 1994, 109: 254.
43. Komai, T., Tsujita, Y. Hepatocyte selectivity of HMG-CoA reductase inhibitors. Drug News Perspect 1994, 7: 279-88.
44. Serajuddin, A.T.M., Ranadive, S.A., Mahoney, E.M. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharm Sci 1991, 80: 830-4.
45. Sliskovic, D.R., Roth, B.D., Bocan, T.M.A. Tissue selectivity of HMG-CoA reductase inhibitors. Drug News Perspect 1992, 5: 517-33.
46. Saheki, A., Terasaki, T., Tamai, I., Isuji, A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 1994, 11: 305-11.
47. Vgontzas, A.N., Kales, A., Bixler, E.O., Manfredi, R.L., Tyson, K.L. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther 1991, 50: 730-7.
48. Duggan, D.E., Vickers, S. Physiological disposition of HMG-CoA reductase inhibitors. Drug Metab Rev 1990, 22: 333-62.
49. Greenspan, M.D., Yudkovitz, J.B., Alberts, A.W., Argenbright, L.S., Arison, B.H., Smith, J.L. Metabolism of lovastatin by rat and human liver microsomes in vitro. Drug Metab Dispos 1988, 16: 678-82.
50. Everett, D.W., Chando, T.J., Didonato, G.C., Singhvi, S.M., Pan, H.Y., Weinstein, S.H. Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 1991, 19: 740-8.
51. Wang, R.W., Kari, P.H., Lu, A.Y.H., Thomas, P.E., Guengerich, F.P., Vyas, K.P. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991, 290: 355-61.
52. Vyas, K.P., Kari, P.H., Wang, R.W., Lu, A.Y.H. Biotransformation of lovastatin-III. Effect of cimetidine and famotidine on in vitro metabolism of lovastatin by rat and human liver microsomes. Biochem Pharmacol 1990, 39: 67-73.
53. Vickers, S., Duncan, C.A., Vyas, K.P. et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1991, 18: 476-83.
54. Cheng, H., Rogers, J.D., Sweany, A.E. et al. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res 1992, 9: 1629-33.
55. Pierce, L.R., Wysowski, D.K., Gross, T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990, 264: 71-5.